Wockhardt reports PAT at Rs 15 crore in Q3
Mumbai: Pharmaceutical and Biotechnology major, Wockhardt Limited, reported the company's third Quarter Results for Financial Year 2020-21.The Company has reported EBITDA of Rs.56 crore (as compared to Rs.27 crore in the previous quarter i.e Q2FY21) mainly driven by enhanced Revenue and Cost rationalisation. Profit after Tax (PAT) for the Quarter was Rs.15 crore against a marginal profit of...
Login or Register to read the full article
Mumbai: Pharmaceutical and Biotechnology major, Wockhardt Limited, reported the company's third Quarter Results for Financial Year 2020-21.
The Company has reported EBITDA of Rs.56 crore (as compared to Rs.27 crore in the previous quarter i.e Q2FY21) mainly driven by enhanced Revenue and Cost rationalisation. Profit after Tax (PAT) for the Quarter was Rs.15 crore against a marginal profit of Rs.4 crore in the previous quarter. Profit after Tax (PAT) for 9MFY21 is reported at Rs.779 crore as against Loss of Rs.117 crore in the corresponding period.
Net Debt-Equity ratio as on 31st December, 2020 stood at 0.49 (31st March, 2020 stood at 0.84).
Wockhardt has further announced that on 30th November 2020, it hosted a visit at its Wrexham facility in North Wales of the Prime Minister of the United Kingdom, Mr. Boris Johnson.
The UK Government has reserved one fill and finish production line at Wockhardt UK for its exclusive use in order to guarantee the supply of vaccines required to fight against COVID-19.
As per the terms of the agreement the company has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID-19, including AZD1222, the vaccine co-invented by the University of Oxford and its spin-out company, Vaccitech, and licensed by AstraZeneca.
In the UK, Wockhardt is one of the largest suppliers into the NHS for over 20 years, has had a presence in Wrexham for over two decades and employs over 400 people at its 612,000 square feet high-tech manufacturing facility.
Business Review:
Quarter ended 30th December 2020:
UK Business during the quarter stood at Rs.301 crore in Q3FY21 (PY Rs.219 crore) showing a growth of 38%. UK Business contributed about 39% of Global Revenue.
Emerging Markets Business of the Company stood at Rs.128 crore in Q3FY21 (PY Rs.138 crore). Emerging Markets Business contributed about 17% of the Global Revenue.
India Business (both Continued & Discontinued Operations) stood at Rs.122 crore in Q3FY21 as compared to Rs.235 crore in Q3FY20. The Continuing Business stood at Rs.122 in Q3FY21 (PY Rs114 crore) registering growth of 7%. India Business contributed 16% of the Global Revenue.
Irish Business stood at Rs.46 crore in Q3FY21 (PY Rs.38 crore) showing a growth of 23%.
US Business stood at Rs.135 crore in Q3FY21 as compared to Rs.213 crore in Q3FY20. US Business contributed 18% of the Global Revenue.
Research & Development expenditure during the quarter was at Rs.42 crore (5% to sales) and including capital expenditure is at 9% to sales.
Capital expenditure during the quarter was Rs.27 crore.
9 Months ended 30th December, 2020:
UK Business stood at Rs.752 crore in 9MFY21 (PY Rs.666 crore) recording a 13% growth. UK Business contributed about 35% of Global Revenue.
Emerging Markets Business of the Company stood at Rs.435 crore in 9MFY21 (PY Rs.414 crore) showing a growth of 5%. Emerging Markets Business contributed about 20% of the Global Revenue.
India Business stood at Rs.362 crore in 9MFY21 as compared to Rs.706 crore in 9MFY20.
Continued operations of the India Business stood at Rs.308 crore (PY Rs.328 crore). De- growth is mainly on account of lower sales in Quality Generics division and in some of the therapeutic areas. India Business continued operations contributed to 14% of the Global Revenue.
Irish Business stood at Rs.113 crore in 9MFY21 (PY Rs.114 crore).
US Business stood at Rs.349 crore in 9MFY21 as compared to Rs.544 crore in 9MFY20. US Business contributed 16% of the Global Revenue. Research & Development expenditure during 9 Months ended 30th December, 2020 was at Rs.124 crore (6% to sales) and including capital expenditure is at 9% to sales.
Capital expenditure during the nine-month period ended 31st December, 2020 was Rs.71 crore.
Intellectual Property (IP):
9 patents were filed during the quarter ended 31st December, 2020 and the cumulative filings till date are 3182. The company was granted 10 patents during the quarter and now holds 752 patents.
|
| Q3 FY21 | Q2 FY21 | Q3 FY20 | 9M FY21 | 9M FY20 |
| Oct - Dec 2020 | Jul - Sep 2020 | Oct - Dec 2019 | Apr - Dec 2020 | Apr - Dec 2019 | |
| INR Cr | INR Cr | INR Cr | INR Cr | INR Cr | |
| Sales | 764 | 714 | 869 | 2,130 | 2,534 |
| EBITDA before R&D* EBITDA % to Sales | 97 12.7% | 72 10.1% | 154 17.7% | 158 7.4% | 373 14.7% |
| R&D R&D % to Sales | 42 5.4% | 45 6.3% | 45 5.2% | 124 5.8% | 165 6.5% |
| EBITDA* EBITDA Margins % | 56 7.3% | 27 3.8% | 109 12.5% | 34 1.6% | 208 8.2% |
|
Exceptional Items # |
- |
- |
- |
1,328 |
- |
| PBT | 31 | (85) | 16 | 1,094 | (132) |
| Profit After Tax PAT Margins % | 15 2.0% | 4 0.5% | 9 1.1% | 779 36.6% | (117) -4.6% |
| EPS (Rs) | 1.4 | 0.3 | 0.9 | 70.3 | (10.6) |
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd